<SEC-DOCUMENT>0001193125-15-307431.txt : 20150831
<SEC-HEADER>0001193125-15-307431.hdr.sgml : 20150831
<ACCEPTANCE-DATETIME>20150831070243
ACCESSION NUMBER:		0001193125-15-307431
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150831
FILED AS OF DATE:		20150831
DATE AS OF CHANGE:		20150831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		151083472

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d51298d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of August, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 31&nbsp;August 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">424 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr&nbsp;Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting CEO</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31 August 2015</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN ANNOUNCES THE OUTCOME</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF A COMPREHENSIVE SCIENCE REVIEW</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>Novogen will focus the development programs for each of our three lead
candidates to achieve the earliest possible initiation of clinical studies. We affirm our goal to have two products enter clinical development in 2016</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>Specific indications, formulations and routes of administration have been
confirmed for each program with emphasis on achieving robust data-driven milestones required to meet pre-clinical and clinical regulatory requirement</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>The Company&#146;s extensive medicinal chemistry expertise and compound
library coupled with its ongoing collaborations with Yale University and the University of NSW enables us to further strengthen, protect and target our future discovery programs and our intellectual property estate</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>Further
management and staff appointments have been made to strengthen in-house capabilities in terms of manufacturing, project management, intellectual property and investor relations expertise</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>High
quality candidates have been identified for the permanent CEO position including some from overseas. Interviewing of final short-listed candidates will commence mid-October with view to announcing an appointment by year-end. Recruitment of a CMO
(Chief Medical Officer) is ongoing</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>The Company is in a strong financial position to support the progression of
the lead programs through to the clinic</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, August&nbsp;31, 2015</B> &#150; US-Australian drug discovery company, Novogen Limited (ASX: NRT;
NASDAQ: NVGN) today confirmed its comprehensive scientific review has identified high value opportunities for its ground-breaking technology platforms in areas of unmet patient need. Novogen is moving as quickly as practicable through the remaining
preclinical projects prior to entering into Phase 1 clinical trials with our 3 lead compounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting Chief Executive Officer, Iain Ross, said that
following his appointment last month, Novogen initiated a company-wide review, including a comprehensive science review, to determine top priorities and enabling the Company to focus valuable resources to achieve high value opportunities in a highly
competitive market place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In keeping with industry best practice and Novogen&#146;s commitment to maintaining a high standard of scientific
integrity, we&#146;ve formed a Scientific Review Committee to ensure rigor is applied to all of our decision-making processes. Committee members include retired Executive Vice President for Eli Lilly&nbsp;&amp; Co and President of Lilly
Bio-Medicines, Bryce Carmine, as well as two eminent academic researchers: Professor Peter Gunning from the University of New South Wales, Australia, and Professor Gil Mor from Yale University in the USA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am delighted to report our Scientific Review Committee has identified realistic opportunities based on the extensive data available for our lead drug
candidates. We have therefore chosen to tighten our focus on significant areas of unmet patient need. Given scientific success we are confident these opportunities will enable us to drive strong value for shareholders,&#148; Mr Ross said. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The Company is in a strong financial position to expeditiously drive our three drug candidates through their final requisite pre-clinical safety
programs and ultimately into Phase 1 clinical trials. This will be our next critical decision point. In line with our business strategy, we will be applying our resources to target opportunities that could generate the greatest return.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Pending the outcome of the required safety studies we are committed to progressing Cantrixil and Anisina to Phase 1 clinical trials in 2016 and
Trilexium by 2017. We will be continuing to work through the necessary regulatory requirements as thoroughly and as quickly as practicable,&#148; Mr Ross said. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Another significant outcome of our scientific review has been the recognition of the depth of our medicinal chemistry expertise across our two
technology platforms. This secures for the Company exceptional future growth opportunities, provides back-ups for our existing lead compounds and opens up new avenues for future discovery. Our actions have also strengthened our existing patent
protection.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Ross said that following the scientific review, the Company had decided to pursue a patent protection
approach for its degenerative and regenerative medicine program known as Jacob&#146;s Hope. This program would now take a lower profile while we focus on the nearer term core opportunities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRODUCT UPDATE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cantrixil </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is the Company&#146;s lead superbenzopyran (SBP) drug candidate designed to be injected into the intra-peritoneal (IP) cavity. We aim to treat
ovarian cancer by targeting both differentiated cancer cells and potentially cancer initiating cells, the cells thought to be responsible for cancer recurrence post chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Therefore, Novogen is continuing to progress Cantrixil through its safety evaluation program and fulfil the necessary regulatory requirements with a view to
starting Phase 1 clinical trials in 2016. As Cantrixil is a cytotoxic drug, safety signals have been identified in the cardiovascular and gastrointestinal systems that require further evaluation. It is important to note that the standard treatment
for ovarian cancer patients has not significantly changed over the past 30 years and their prognosis remains exceptionally poor with as many as 80% of these patients suffering a relapse and ultimately an early death. Therefore an urgent unmet
clinical need remains for all ovarian cancer patients. The Cantrixil preliminary safety observations have been discussed with the Medical Study Committee who concur that the benefits to ovarian cancer patients may significantly outweigh the
associated risks while on treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen will inform shareholders once these evaluations have been completed. Assuming success the Company will
progress to clinical trial in Australia focussing on late-stage ovarian cancer patients who may or may not have associated malignant ascites using an intraperitoneal mode of delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>While it is not possible at this stage to be precise as to when clinical trials will commence, the Company continues to target 2016 to commence a
first-in-human trial for Cantrixil in Australia. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anisina </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina is the Company&#146;s lead anti-tropomyosin (ATM) compound, which is a unique first-in-class anti-cancer agent. This small ATM molecule targets a core
protein component of the actin microfilaments, tropomyosin Tpm3.1, essential for tumor cell survival. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pre-clinical evidence available supports the entry of Anisina into the regulatory required safety
evaluation program. While this program is progressing, the Company will continue to evaluate the potential lead adult cancer indications to target in the clinic. This evaluation will guide us towards decisions that support a pediatric neuroblastoma
program for Anisina where it has been shown to enhance the efficacy of anti-microtubule agents when assessed in pre-clinical models of human pediatric neuroblastoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending a successful safety evaluation outcome, <B>the Company is targeting 2016 to open an all-comers Phase 1 clinical trial in Australia, </B>where the
primary outcome will be safety. Novogen has re-affirmed our commitment to pediatric neuroblastoma and has assembled the relevant therapeutic medical experts to participate on an Anisina pediatric oncology board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trilexium (TRXE-009) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRXE-009 is the Company&#146;s
second lead SBP drug candidate and our least advanced drug candidate. The Company has identified a high value opportunity where there are currently no approved treatments and the current life-expectancy for patients is no more than 8 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our collaboration with a local pediatric medical oncologist, the Company has confirmed that Trilexium is exquisitely active against patient derived
explants of Diffuse Intrinsic Pontine Glioma (DIPG) in pre-clinical studies. DIPG is an aggressive but rare brain tumor primarily affecting children. Novogen has identified a drug formulation that in animals is able to deliver Trilexium to brain
tissue and researchers will soon commence a proof-of-concept pre-clinical study in an orthotropic model of DIPG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once this proof-of-concept study is
completed, the Company plans to commence the required safety evaluation program. By targeting DIPG, the Company anticipates that this strategy may provide a fast-to-market opportunity and is also planning to file for an Orphan Drug Designation
status with the FDA. <B>At this stage, first-in-human trials are targeted to commence by 2017</B>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen
group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)] yielding drug candidates that are first-in-class with potential
application across a range of degenerative diseases. Given the encouraging data from in vitro and in vivo pre-clinical proof-of-concept studies in the field of oncology, our immediate focus is to undertake their respective toxicology programs. Our
target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. While the initial target pediatric indication for Anisina has been identified as neuroblastoma, we are yet to identify the adult indication
and are intending to open an all-comers Phase I trial initially based on our pre-clinical studies. For more information, please visit <U>www.novogen.com </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Director, Novogen Group
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com / </U>Ph: +61 (0)&nbsp;2 9472 4109 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release
contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such
words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148;
&#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#146;s drug development program, including, but not limited to, Cantrixil, Anisina, Trilexium, and any other statements
that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production
and marketing of the Company&#146;s drug components, including, but not limited to, Cantrixil, Anisina, Trilexium, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Cantrixil, Anisina, Trilexium, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual
property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil, Anisina, Trilexium, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission
including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties
mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51298footer.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g51298footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51298footer.jpg
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M P,# __  !$( #H"Q@,!$0 "$0$#$0'_Q #*  $  @(# 0$!
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MWEZZM1ZS/)(T$_)83W;?0 I$;<(;*2*J]D7\AUOSE-\K;(Y>C2$ 0! $ 0!
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M%>F-VT=C$MRN+ZURMR7]ZJ70D;6CBCB8V.*-D4; &LCC:UC&-&IK6- :UHV
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M,0]PT"&87=N/Z&[#Y*<FB0*5#/OQVJ275W%%E>DMVW:RL.Y:ER/Q+JEI[3]
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M5;'"! $ 0! $ 0! $ 0! $ 0! $!?L/YD<2XB"WL^\M;^RM6-BB@O(/ALA8
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M^Z7-TT8#3E6B>7XDXQ6OC+3'W'^'.-R]<JXM.B7$ZZW]!M?:=JAG0! $ 0!
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MT\"6I+B1]HW#N#=OIS 6[]VQ:MU\4I-UE.7#*3X^)))):$J&P%%+H( @" (
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J9#KY?3K7@G'Q $ 0'-FOT?A" [4 0! 26+^LG7X,GX-: GD 0! $!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g51298header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51298header.jpg
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M P,# __  !$( #X"Q@,!$0 "$0$#$0'_Q #)  $  @(# 0$!
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MW0L7IZQBZ=A O\4X?CZ7+L=[F6K[JFD,AYP8J'B;C<5>7K@2&R74D=E$:=O
MT7$U#Z0TK?#!F_&TEVE3>\RV(Z8]N4G^DU%>UE&R'FKU1=ES;5]GC(R" +6W
M$DPJ?\>Y=,>(#M#6J3'#LQU=6^GZBJO<?XA=T@X6X_HK7M=2CW^7RN4?QY'(
MWEZZM1XF>21H.OR6./+9M[ %(C;A#PI(JKV1?R'O7YRF^ED<O1I" ( @" (
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M ( @" ( @" ( @" ( @(S);(?6_XFH"*0! $ 0'RY[6[3[.WN0'49Q\UI]J
MZS,\]H'J']=4"VFG+YC&9#(.8QC'.OKISBQK6ESG3/)<XM +B2=I4V+;BJ\Q
MS%V,8Y,Z)*LGZS%63 0$/U#_ +#F/]!-\06RU]Y#]8B9_P""O?RF>?U;'"A
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M>%]9+KP;P@)3$_O)^C=\80%D0! $ 0! $ 0! $ 0! $!R 2"0#0:D]@&\G8
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M66./T"LA^  ?"@)&+#VD="\R3'0T<>!NG86LH3WH"4:UK0&M :T:!K0  -P
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M*F&9KAV-D:6GO;Q!9&I'28^\CK6!Y [64>-E3\DDK ,0@@T((.XC7N0'" (
M@" ( @" (#*CLKJ459!(0=CBWA;WN+11 2$>$G=0RR1QCM#:O<.ZC?A0:GK?
MRPP]HWHS%&0RS.YN0VNX&_O]QV, /9O51F*F1+T>H[S@/]MAUR_:D;*CMK>'
M]%#'&=[6CBUV^\:N^%1BY.Y $ 0! $ 0! $ 0! $ 0! $ 0! =,T#)VAKZBA
MJ"TT(W[010H# ?CC^KD!]#Q3X17XD!BOM+AFV,N&]GO? -4!CD$&A!!W$4*
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MQ%O^7^\S] ?X=TX1FT_]U#_MGO%<Z?80@" ( @" ( @" ( @" (#\WOM;?\
M]0LO_P AA_XS*KIN#_A'^N_4CX9_D;_]#'_XUOUS/+ZM3@@@.ZWMKF[>([2W
MGNI":<%O#).ZIV5$;7$>U&TO%H>[=NY=>[:C*3Z$WZBUV?0/4]\PDV+;%CF.
MH_(2MM]"TBO*;S)]-W"%HEDV8\M>HL[7 N)7XOW-R--LG3NU?<:VQ?D(P!KL
MWU"\NK5T&)M0UORMGBKMSB:C]D%(EQ/>UA#M^HB8_DU/WLN_KS07ME]!M/I?
MRLZ(Q&2Q<C,1X^XBR%E(RYRD\MX\/9=1.8\1$LM6N:X5%(]"H5_,R)VY+>HJ
M/9H=#@>7>$XM^W*-K?N*Y'63<OM+DV=Q[VX&,+@QC&"NQK6M&AW !<^VVZL^
MM[L5HDDCY>QD@H]C'C91[&N'<X$)5K8S$HQDJ22:Z2-FPV.FK^8Y3C\Z%SH_
MQ:EGP+9&]..UU(MS!QKGV=U]&GU$7+TV-3!=4W-F97\=A_[5M61^<B)/A>G\
M*>O2OH(J;"Y&']3S6_=0N#^]ONO'<MBNVY<I$N8.3;^SO+HU^LC7QR1'AD8^
M-VZ1KF'N< MB:>PBM2BZ233Z3Y0P$ 0'7)%%**21L>/[303["14("/EQ%I)J
MT/B/[-VGX+@X=U%D$?)A)!^AF:[T2 L/>.(?$@(^7'WD5>*!S@/G1_G!^+4K
M ,?E2_X4GX#OZD!W1V5W+3@@DH>TMX6][J!9%20BPL[OTLC(Q78VKS3N:/A0
M:DA%AK5GRS)-]\> =S*'X4!GQ6T$/Z**-GI#17\(U<@H=ZP @/4WEI_PW%_2
M9#^/N%4YGW[]'J.\X#_;8=<OVF7M12Y" ( @" ( @" ( @" ( @" ( @" (
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M[#16/]9A+1P<7SUJ<9/_ !G?MO>CDQN0YMW<E3K;DJF$_P F&].4?=]*7D_
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MR&W:^E>'FR.:'.IV-J0M=R];M>-DO&P<K+J[$*P7+HEVLN]EY97C^%V0R4$
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MW6W.CYJ-KU%=FBCC-([F&X&^)MPWVTG@BHMFTARBD]&FO3[4CH63R$ 0! $
M0! $ 0! $ 0$7FO]LGV?*@I6G^,S97MI5;;/WBKL(?$*?*2Y]*==2A*:<\$
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7@.U $ 0$CC?WD?1/_*" GT 0! $!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g51298tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51298tx_pg03a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C0+& P$1  (1 0,1 ?_$ .   0 !! ,! 0
M       % 08'" (#! D* 0$  04! 0$!            !0$" P0&!P@)"A
M 0,# @,"!@@/#00(!P$  0(#!  %!A$'(3$2$PA!46%Q(A2!D;$R4Y34%?#!
MT4)2LB,S<[-4E=4V":%B<B0T=+0U5746=M9#9+66X6.3TT0E%S?Q@I*BPF56
M&1$  @$# 00%!P@(! 4#!0    $"$0,$!2$Q41)!87$3!H&1T2(R(P>AL<%2
M<K(S%$*2TG,T%34(\.%B=(+"4],6DR08HD.S)1?_V@ , P$  A$#$0 _ /W%
M$G4\3S/A/CH"FI\9]LT U/C/MF@&I\9]LT U/C/MF@&I\9]LT U/C/MF@&I\
M9]LT U/C/MF@&I\9]LT U/C/MF@&I\9]LT U/C/MF@&I\9]LT U/C/MF@/+.
M),*5J3]Y5[HH"R*=72"Q<DW!L>/A<=M8NER&J?5(KB>S94"/Y5)!4AK16FJ4
M]2_(*V+6-<N;7ZL>+(C.UG$PV[<7WE_@MWE9@'(<QO>2.'UZ1V<1*^IFWQ]6
MHK1'O2I(]-]P?9+)/BTJ3M68652&\Y#-U'*SI/OG2W]5;E]+\K+8ZC]!5]6L
MIH#J/T%7U: =1^@J^K0#J/T%7U: =1^@J^K0#J/T%7U: =1^@J^K0#J/T%7U
M: E+5?+I99(EVV8[&>X!72=6W4@Z]#S1!;=1KX"#Y-*LN6XW(\LMQL8^5D8E
MSO<>3C/_ !T;C.F.;IVZ?V<6^-IMDHZ($M!)@.JY KZM5Q"H_9%2>/,5'7,.
M4=MO;$ZO"\06+S[O,7=W/K?HM_1\IE5"T.(2XVM#K:TA2'&U!;:TGDI"TDI4
MDCPBM-IIT>\Z%.+7-%IQ?2MS.5"HH!0"@% * 4 H!0%UV0GU-?X97N-_5H"6
MU/C/MF@&I\9]LT U/C/MF@&I\9]LT U/C/MF@&I\9]LT U/C/MF@&I\9]LT
MU/C/MF@&I\9]LT U/C/MF@&I\9]LT!Q4X$#J6OI3XR3[0',D^*@(MZXJ/HLZ
MI!YJ(]/SIUY:^7C0$<5*))*E$DDDDDDZG7B: IJ?&?;- -3XS[9H!J?&?;-
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M!E6S+W;WQ>U?Y>0SYCFX-DR#LXZUBV7)6B?5)3B>S>5IRB2?1;=.OUIZ5Z>
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M7JPSB@)6TN+$@MA1Z%-J)3KP)!!!T\!H"XZ 4!4<CYOIB@!YGSGW: I0"@%
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M 1ERY,^=?N)H"*H!0"@% * 4!Q4M*.9]CPT!@"=8X2+[=ISJ?67G[G+>2ET
MM-=;ZE)"6^*5*3XSKQ\ J2C<;MQCT4./N8EK\Y=N2VR<Y/;T5?\ C:>LG7P
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MMJ/M);54I0"@% * 4 H!0"@% * 4!&7+DSYU^XF@(J@% * 4!XG/?J\] <*
M4!B:Y_UC/_GDC\8JM^'LKL.:O_Q,^U_.>&KS&* B;_\ U'=O[OE?BC5]KVUY
M/G-//_@KW[I_,S7JI4X,4 H!0"@% * 4 H!0"@% * 4 H"XL?RJ]XT]UVZ42
MPI?6[!?U=AO:\^MDD="R/KD%*O+6&[8MW5M6TD,'4\S3I<V/+U'OB]L7Y./6
MJ-&;+=NIC,]F+'N\EC'[A*D,QF6[@^VW#E2G$N%#,28YT-]HYV9Z4+Z5$C0:
MU'3P[T&^1.44JNG0CL<;Q-I^1&,<J<;-Z3HE)TC)NM%%OI=.DOOR^ \0?&"
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M[Y7XHU?:]M>3YS4S_P""O?NG\S->JE3@A0"@% * 4 H!0"@% * 4 H!0"@%
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M+4E224J!!&H((\7.@*4!XG/?J\] <* 4!B>Y_P!8S_YY(_&*K?A["[#F;_\
M$S?15_.6/>LMMEIZFFUB=-&H]784.S;5_P!>_P 4H \('4KR5L6[,YOA$A\S
M5K&+6$?7O<%N\YBF[9%=+RI7K;W0QKZ$1DJ1'1XM1KJZKRJUK>A9A!;%MXG,
M96=DY;I<E2'!;B#K*:8H!0"@% * 4 H!0"@% * 4 H!0"@% 8GWF_5!G^_('
MXB;6[I_X[^R_H.9\6_TN/[Y?=D:N5,GFI]1>X/\ J/N#_F^W?\#37(^(_P >
MW]C_ )CZ"^#G](S?]S#[B-\*YT]?% * 4 H"HY'S?3% #S/G/NT!2@% * 4
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M!X]:GL:Q%6XSEMDXKR'EFL:CDSS+UB#Y+<;DELZ:/>S'%;:5"!%5 H!0"@%
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M\C3G=GE^JY6Z>TW9YG%K>Y1?2:P_LM+Y.VGS[?\ [H&1X1F^U*+&O'MZ=K,
MW,5;DYA$Q#(;9;[!EI<%KESK;(CN9%!:EH4PZM($E75HH* F_&]N.=BXOB"W
M=MWW).U=G;KR\Z;<:U2:?*Z;>'8>:_VR:A>\-:WKOPIU##S=,5EVM0P\;,<>
M_5F["-J_7DE*+CWL83]5NG.Z[:I:K]X+N[;@]YKOM]_K;?;3:O:#,KW=+3L-
M%D;D[EWU=DO>RB9.*6-Q&4X0F+!ES;A<;@U#<9DMM=*NS;0-%A729[2]6Q=&
M\.:7EYE^_;MUO^[MQYHW:2?JRZ**O2F>7^./ .N_$?XS^.= \.Z7I>9F3AIJ
M>7E7.[N8"=JW[ZQ2+E*4U%J=*-**WUY7]@^\-W;+)NOW.KOL;F]ZD72YXEMC
M9Y5ES];)7=[?N!MCC3<FS9Q$+KAD,RY%QM:^V':!;D:2Z@JU5K7GNDZQ<P/$
M"U'&BE;N7FI0Z'"Y/;#A1)JG!H^M?'OP[P_$WPBN^#=8O2NY>)IL)6\IKWD<
MG$LUAD)UJG*4&IT=7"<D]K-?/V4V+JR#8JY]ZK,KNK+]ZN\]?I]^S[+I;"&Y
M3-IPV=*Q'&L4AD#[G;K>U:ER%A&B%O/CA]S3I*^-[_=:I'1<>/=Z;A14806Y
MN:YY2?6^8X;^V+27F^"KOQ-UF]^;\8^([\KF3?E%)J&/*5BU9CPC!0<GQDUT
M0BCZBUQ1]*E1S]@^X: @GOOKOX1?VQH#KH!0$+?\=L^3P%VV\Q1)8)ZVEI/1
M(BN\NVBO@%3+FG Z:A0X$$5DM79V9<T-_P _::F;@XV?9[C*BI0Z.*?%/>F:
MQY?LY?+)VLRQE=^MJ-5J;:;";G&;&I)<CH)3)2D<U->EXTBI>QG6[FRY2,S@
M-2\+Y>'6[B5NX^^GZ:XU73Y##A!25)4%)4E12I*DE*DJ2=%)4E0!2H'@0>5;
MR=54YEIIT=4^O84JI04 H!0"@% * 4 H!0"@% * 4!Z(L25.?3&AQW9+ZSHE
MME!6H\-=3I[U(\).B1XZME.,=LMB,ENU=O2Y+47*;Z%_C8NLRC9]M@I =ODE
M:%D#2'"6D% /$=M(*5@J\B1[)K1NYM'RV]QT>+X?]7FS)-2^K%KY7M%XVV"6
MR[9)*EK2-3$FJ3JO3P-24A "B.&BAQ/UPJEO-JZ7-Q3+\/I1YL-MR^J_HE_D
M8)S;;/.<[@QL7QG'ILZ[_/<%Q]"TB-&@QT-2TN2YTU_ICQXK96/2*CU:CI"B
M0#*XV9C8\G>N2I#E?E.*UO0=7U:S'3L&Q.67WJ;3V**Y9>M)O8EUU-AMG.YO
MBN$R(.1Y]*9S+)(RFY,:V(:*,7M<I&BD*[%T!^\/QW!JE;H0UU#4-G@:C\[7
M+M].UC+DLOI_2:^@ZSPQ\+]/TF4,[6)1RLZ.U1I[J,N--\VO]5$GN1ND23SY
M^P/: Y "H$]4ZRE * 4 H!0%1R/F^F* 'F?.?=H"E * 4 H"BE)2-5$ #PDZ
M4!X'9AXAH</LR-?_ *0>% >!2BHZJ))/A/$T!2@+<R#$[)DK>EPBA$E*=&I\
M?1J8W]B"YH0\VG[%8(\U9K=^Y:?JOU>!'YNF8F='WRI=Z)+8UZ3"L_:;(6)@
M:M[L.=#6K5$M3R8RV4D\!(85U*ZD@_[,K!\G*MZ.;::K+8SE[GAS-C<<++C*
MT]S;2\Z,B8]MI9K*CUF?T7BX!"U!;S>D)A703]PBJZ@M23R4YU'P@"M:YE7+
MCY5LA4F\+0L7%CWM[WMZG3[*?4NHMH^UIX. '#Q   <*S5JC4HEL6XI52@H!
M0"@% * 4 H!5 <'&T.I*'4)<0>:%CJ2?8/*JIM;MY248S7+-)Q+;FXZ#JY!5
MT\SZNX?1/X-P_N!59H7FMDB+OZ:O:L-TX/Z"UW6G65EMYM32QS2L$'V/ 1Y1
MJ*V$T]J(J4)0?+-4D<*%HH!0"@% * 4 H!0&R>$66RW_ &_M=NO]ELU_MXF3
MWA OMJM]X@A],U[I?3$N4:5'2\ >"@GJ\M1>1=NVLISM3G"=%MBVG3AL:.UT
M["P=0T:W8S[%F_8YI/EN0A<C7F='RSC)57&E3(;EOMKMO-H=MEN<M!B^HJM#
MD"(NU*A %(AFV+95!,0)X=EV?9Z>"M53FI]XI25RM>:OK5XUWU)J6-C3Q_RD
M[5N6*X\K@XQ<.7ZO(URTZJ4ZCH>LMDDQH,*39+-)AVMR.]:X<BU6]^):WHB>
MB*];(KL=3%O>BHX-+92A38X)(%7*[=4G-2DIRWM/?V\2R>%A7+<+-VQ9E9M-
M.$7"+4''V7!-4@UT.-&CMD6VVS)<.?,MMNF3[:IU5MGRX$23.MJI "9"K=,?
M:7)@JD)2 LM*05@:'6J*Y<C%PC)J$MZ3V/M1?/&QKMZ&1=MVYY%NO).48N4*
M[^233<6UL;BU7I*QK;;(,B=+@VRW0I=T>3(N<J' AQ)-SDI!2)-QD1F&GI\@
M!1T<>4M?$\>-)7+DHJ,Y2E%;JNM.I<$4M8N+8G.[8M6H7;KK.481BYM=,FDN
M9];J^L\EUQ[';ZY">ON.V"^O6U17;GKW9+7=WK>LJZ^N [<8DER$KJ&NK92>
MKCSJZW?O6DU:G.*>^DFJ]J3HS%E:;IN?.%S/Q\>_<M^R[EJW<<>GU7.+<=NW
M9TDA,BP[C'?AW"'$N$&4WV4F#/BQYL*2UP/928DIMZ.^UJD>BM)3P'#A6.,I
M0DI6VXR72FT_.MIL7K5K)MRLY,8W+,E1QE%2BUP<9)I^8C;7C>-V)QYVQ8WC
MUB=D-H:D.V6Q6FT.R&D*ZT-R'+=#C+?;0LZA*B0#QYUDN7KUW\6<I)<6W\]3
M7Q=-TW!DYX.-CV)R23=NW"VVEN3<(JJ714[5V*PN&Z%RQ61PWQ*$7PN6>VK-
M\0V EM%Z*HI-W0VD:)$GM0D<M*IWUU))3FE'V=K]7LX%SP,"7>5L6/?_ (ON
MX^]IN[RJ]>G1SUIT'NC1HT.,Q#A1HT*)%:2Q&B0V&HL6,PV.EMB/&80VQ'9;
M2-$H0D) Y 58VY-RDVY/I>\SVK5JQ;5FQ&,+$52,8I*,5P26Q+@E1+@<9<.%
M<(K\&XPH=Q@RFRS)@W",Q-A26E$%34F)*;=CR&B4CT5I*=1RI&4H24H-QDNE
M.C\Y;>LV<FT[&3"%RQ+9*,XJ49+@XR33\J.UAIF*TS'BLM18\9M#,:/&;;CL
M1V6DA+3,=EE*&F&FD@!*4@)2  !H*.3E+FEMD]Y="$+4%;M)1MQBDE%422W)
M);%3@J$5_AS&_F^19_\ #>._,\N0J7+M'S%:OFF7*6XAY<J5;!$$&1*6\VE9
M<6VI94D$G4"LG?WN=7.>7>K9S5=:<$^A&K_+=-_+2P_R^.L2<N9P[JWR.5:\
MSAR\K;>UMQJ^)[9MNMMRAKMUQMMON-M=0VAVVW&#$G6YQ#*D+9;<@RF78CB&
M5MI* 4:)*01IH*LC<N0GWD&U/BFTZ\:K:;%_'Q<FR\?)M6[F.Z5A.,90V;ER
MM.-%T*E#R6O'\>L7;&Q8]8;$9/9^LFQV6V6?UGLNKLO6?FZ+&]8[+K/3U]73
MJ=--:NN7KUVG?3E.FZK;IYVS#BZ?I^!7^7X]C'YJ5[JW"WS4W5Y%%NG14+Q_
M'76KI'=QW'W8]\=#][CNV2UN,7J0DA2)%Y97$+5UD)6D$+D!Q0(U!U JO?WJ
MJ7//FBMFU^KV<"CT[390N6Y8V.[5YUN)VX4N.M:W%R^NUT.?,=S]HLTI%O:D
MV:T26K0ZR_:&Y%L@R&[2_&0&X[]J0]'6BW/QVTA*%LA"D)&B=!5%=N+FY927
M-OH]_;Q3Z3)/#P[L;<+MFS.-EUM\T(OD:V)P3346EL3BDTMS1V&VVQ5Q3>%6
MRVF\(BF"B\&!#-W1!*RX82;F6/7A#+A*NR[3LRHZD:U;SSY.[YI=U6O+797C
M3B5>+C/)_.2MVWF<O+WG+'O.7ZO/3FY>GEK2O0&;=;8\R7<8UMM\>XW!+*;A
M<6(,1FX7!,9/1&3/G-,HE34QT>BV'5J"!P3H*J[DY05MRD[:W)O8NQ=!6&-C
M6[T\FW;MQR;E.>:C%2G3=SR2K*G1S-T6Q'K4E*DJ0M*5H6E2%H6 I#C:TE"V
MW$*!2M"TD@@\"*L[#*U&47&23BU1I[J<&>6!;[=:HC4"U6^!:H#'7V$"V0HM
MN@L=:RXL,0X;3,9D+<45'I2-2=3QJZ4YSES7&Y3?2W5OM9BL8^/BVE8Q;<+5
MB.Z,(J,5V1BDEY$>NK3,5'/V#[AH"">^^N_A%_;&@/#+G0K>V'9TN/$0=>DO
MN)1U: 'T4D]2O8!JJC*6R*;9CNWK5E<UV48KK9',9+8)"PVS=X96HZ!*UJ:U
M4? "ZE"?W:O=JXE5II&"&?AS:4;D*LF^>A'$$:@CB"/&".!%8^TVJ[*E=3SU
M.M"I866;<XYEH6])CF!<R-$72"$MOJ(][ZVWH&IB0>?4 KQ$5LV<J[9V5YH<
M&0^I:'@ZDN:<>2_39*.^O6MTEU?*:PY7MMD>)E;[[!N-K3KTW2"A;C*4Z\/6
MVO2=B+TYE7H:\E&I>SEVKVQ-*7!G ZEH6=IK<IKO,=?IQW=C6^+XUV&/ZVB$
M% * 4 H!0"@% * 4 H#DE"EJ2A"5+6HZ(0E)4I2CR2E*022:HVDJLJHRD^6*
MK)]!D.Q;>SIP;DW9:K=%5HH1P$JG.I.A&J5:HCA0^RU5Y*TKV9&.RWM9.X6A
M7KU+F5ZEKA^D_-N\IEVVVBWVA@1[?&;81H.M6G4\Z1]<\\K[HXKSG0>#2M"=
MZ=SV]YU&/C6,2')CQ45\K[62C;;CJPAI"G%J/!*023[0X#R\JQ&RHRD^6*JV
M7)#Q\^BY.5IX>P;5^XXX/!Y![=6NXDFD2%K!Z;K\B+MA*,,@1M&DI3H$) ""
M!]DGZ[V>-8FV]Y(1C&"Y8I*/47$Q<6G-$NZ-+\!&O9D_PB=4>S5"XD?+X_H]
MF@% * 4 H!0%1R/F^F* 'F?.?=H"E * 4!XW9B$<&_34/#]:#_\ E0$>XXMP
MZK43Y/ /,* ZZ 4 H!0"@.*_>.?@W/M%55;UVELO9?882J06XYE[Q52@H!0"
M@% * 4 H!0"@% =$B-'E-]G(:2X..AY+3Y4+'I)(I%RBZIF*[9MWE2XD_G\Y
M:DZP/,:N0R9#7/LCH'D#R:<'!^[Y*V874]DO:^0BK^G3@G*T^:/#I_S+?(()
M!&A2="#P((\!!X@UE(ZC%"@H!0"@% * 4!M+MG^I=L_G%Q_IKM0^7_$/L1W^
MA_TRWVR^\R_*UR6% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * \LV="MD5
MZ?<9<>!"825/2Y;J&&&TZ'BIQ9 UTY :D^"KHPE.7+%-R9CNW;5BV[UZ2A:6
M]MT7^.HPW>=R([J5_P"'DB0V_JXU<GT$-J0OTD+C,*"5*!2K4*7IYJVH8S3K
M=\WI(2_KD'%/"]9->TUL[4F8PES)4]Y4B8^[(>6=5..K*CY@#Z*$C7@  !6R
MDHJBV$#<N3NRY[C<I=?T'F^G52PNBRY;=K-TLI<];A< 8<A2B$CC]X=XK9/'
MD-4^2L<[4)K=M-_$U+(Q/57K6OJOZ'T&7;-D]JO8"67NPE::JA2"$/:GX%7O
M'T_P>/DK1G:G;VO<=)C9^/E;(.ESZKW^3CY"X:QFZ.!!20%)4"E25 %*DJ&B
MDJ2>"DD<P>!H'1JC1B#+MGK%?B[-LQ38;HH%12TCJM<EPZ<7HJ?2CJ4>:FM!
MXTFMZQFW+>RYZT/E.9U+PQB9=;N)2SD=7LRKQ71Y*&M&18E?\5DF/>8#K"5$
MAB8V"[!D@'@6921V9)'UIZ5CP@5+6K]N\D[;VG!9NG9>GS[O*CR\'OB^Q^DM
MNLQHB@% * 4 H!0%"=.- VEM>XN^Q87=[T$/*1ZA!5Q,F0@A3B?]W9/2MWJ'
M(G1/EK6NY-NWZN^1*8>DY.7ZS7)9XOI[$9ELN,6FQH!BL=I)TT7-?T7(/C[-
M6@#*#XD@>4FHVY?G<V/<=7B:=BX<?=JMQ_I/:_\ (N#GP'$\!P&IU\PYDUAH
MS?["=A6*0_TN228S//I(';+'B"3J$ Z\S5DII;%M9MV<.=SUKFR)=4:+'AHZ
M([:4#ZY1]):_*M9&IK'*3EO)2W:MVE2VJ?.>BK3(<T<_8^F* [: ]4>8]'/H
MJZD>%M7%/L>(T!-,367]$Z]FYRZ%$<>'UJAP4/:- >R@% * 4!4<CYOIB@!Y
MGSGW: I0"@(^8]R:2>&G4O0^^X\$\#RTH"/H!0"@% * 4 H#BKWB_*A8_P#L
M-56]=I26V+[#"9&A(/,<ZD%N1S&\I52@H!0"@% * 4 H!0"@% * 4!;&0P4A
M G- !06EM_\ ?!1(0YPX=6HT/C'&LUJ>WE>XBM1L1Y>_BO6K1^7I+4K8(@4
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1%0FS<?NUVY?DT+QC_>Z _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
